[1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229 − 63. https://doi.org/10.3322/caac.21834.
[2] Han BF, Zheng RS, Zeng HM, Wang SM, Sun KX, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 2024;4(1):47 − 53. https://doi.org/10.1016/j.jncc.2024.01.006.
[3] Zhou JL, Xu Y, Liu JM, Feng LL, Yu JM, Chen DW. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol 2024;93:102693. https://doi.org/10.1016/j.canep.2024.102693.
[4] Wang SM, Zheng RS, Li JY, Zeng HM, Li L, Chen R, et al. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN. Lancet Gastroenterol Hepatol 2024;9(3):229 − 37. https://doi.org/10.1016/S2468-1253(23)00366-7.
[5] Zheng RS, Wang SM, Zhang SW, Zeng HM, Chen R, Sun KX, et al. Global, regional, and national lifetime probabilities of developing cancer in 2020. Sci Bull (Beijing) 2023;68(21):2620 − 8. https://doi.org/10.1016/j.scib.2023.09.041.
[6] Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br J Cancer 2015;112(5):943 − 7. https://doi.org/10.1038/bjc.2014.606.
[7] Sasieni PD, Shelton J, Ormiston-Smith N, Thomson CS, Silcocks PB. What is the lifetime risk of developing cancer?: the effect of adjusting for multiple primaries. Br J Cancer 2011;105(3):460 − 5. https://doi.org/10.1038/bjc.2011.250.
[8] Wang HD, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, Levin-Rector A, et al. Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2071 − 94. https://doi.org/10.1016/S0140-6736(12)61719-X.
[9] Li M, Wen X, Liang X, Liu MW, Zhang L, Zheng R. Global, regional, and national lifetime risk of developing and dying from lung cancer in 2022: A population-based study in 185 countries. Chin Med J (Engl) 2024;137(24):3101 − 7. https://doi.org/10.1097/CM9.0000000000003368.
[10] GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 2025;406(10513):1873 − 922. https://doi.org/10.1016/S0140-6736(25)01637-X.
[11] Yin P, Brauer M, Cohen AJ, Wang HD, Li J, Burnett RT, et al. The effect of air pollution on deaths, disease burden, and life expectancy across China and its provinces, 1990-2017: an analysis for the Global Burden of Disease Study 2017. Lancet Planet Health 2020;4(9):e386 − 98. https://doi.org/10.1016/S2542-5196(20)30161-3.
[12] Fernandez-Bussy S, Funes-Ferrada R, Yu Lee-Mateus AY, Vaca-Cartagena BF, Barrios-Ruiz A, Valdes-Camacho S, et al. Transforming lung cancer diagnosis: the role of robotic-assisted bronchoscopy in early detection and staging. Lung Cancer 2025;206:108646. https://doi.org/10.1016/j.lungcan.2025.108646.
[13] Li JN, Zhu LP, Kwok HF. Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment. Drug Resist Updat 2023;66:100904. https://doi.org/10.1016/j.drup.2022.100904.
[14] Li WZ, Liang HR, Wang W, Liu J, Liu XW, Lao S, et al. Global cancer statistics for adolescents and young adults: population based study. J Hematol Oncol 2024;17(1):99. https://doi.org/10.1186/s13045-024-01623-9.
[15] Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol 2023;20(9):624 − 39. https://doi.org/10.1038/s41571-023-00798-3.